ELOX

Eloxx Pharmaceuticals (ELOX)

Eloxx Pharmaceuticals Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ELOX

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/04/16	20 : 30	GlobeNewswire Inc.	Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
2024/04/02	05 : 02	Edgar (US Regulatory)	Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
2024/03/30	05 : 11	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
2024/03/22	03 : 20	Edgar (US Regulatory)	Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
2024/03/15	05 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
2024/03/14	00 : 42	GlobeNewswire Inc.	Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
2024/01/27	06 : 33	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
2024/01/27	06 : 33	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
2024/01/27	06 : 32	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
2024/01/27	06 : 32	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
2024/01/25	11 : 44	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
2024/01/25	07 : 11	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
2024/01/10	07 : 10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
2023/12/29	06 : 11	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
2023/11/14	06 : 15	GlobeNewswire Inc.	Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
2023/10/17	06 : 26	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
2023/10/09	21 : 00	GlobeNewswire Inc.	Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
2023/09/21	05 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
2023/09/21	02 : 26	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
2023/09/19	21 : 00	GlobeNewswire Inc.	Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
2023/09/18	21 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
2023/09/18	20 : 00	GlobeNewswire Inc.	Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
2023/09/16	06 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
2023/09/07	23 : 14	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
2023/09/07	22 : 00	GlobeNewswire Inc.	Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
2023/08/30	05 : 32	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
2023/08/22	05 : 50	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
2023/08/15	00 : 56	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
2023/08/14	21 : 30	GlobeNewswire Inc.	Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc
2023/08/14	21 : 00	GlobeNewswire Inc.	Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome	NASDAQ:ELOX	Eloxx Pharmaceuticals Inc